Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03943693 · ClinicalTrials.gov registry record · Early Phase 1
Dual Versus Single Shock for Cardioversion of Atrial Fibrillation
A Early Phase 1 study, sponsored by University of Oklahoma.
- Terminated
- Registry status
- Early Phase 1
- Development phase
- 5
- Enrollment target
NCT03943693 is a Early Phase 1 study that was terminated before completion, run by University of Oklahoma. The registered enrollment target is 5 participants.
The verdict
NCT03943693, a Early Phase 1 study, was terminated before completion, sponsored by University of Oklahoma.
- TERMINATED
- Registry status
- Early Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The investigators aim to investigate the immediate success rate (rate of termination of atrial fibrillation) of dual shock cardioversion compared with standard single shock cardioversion in patients with baseline characteristics adversely influencing successful cardioversion. Baseline characteristics known to reduce the success rate of single shock cardioversion include: increased body mass index (BMI), chronic obstructive pulmonary disease, sleep apnea, enlarged left atrium, longer duration of atrial fibrillation and use of amiodarone.
Interventions
- DEVICE Double shock
- DEVICE Single shock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2019-04-01 |
| Est. Completion | 2021-05-31 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03943693
The ClinicalTrials.gov registry entry for NCT03943693 describes a study currently listed as terminated, categorized as Early Phase 1. The registered enrollment target is 5 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Oklahoma, which has 358 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Double shock is the first listed.
NCT03943693 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03943693 about?
NCT03943693 is a clinical study titled "Dual Versus Single Shock for Cardioversion of Atrial Fibrillation". The investigators aim to investigate the immediate success rate (rate of termination of atrial fibrillation) of dual shock cardioversion compared with standard single shock cardioversion in patients with baseline characteristics adversely influencing successful cardioversion. Baseline characteristic...
What is the current status of trial NCT03943693?
This trial is currently terminated. It is a Early Phase 1 study. The enrollment target is 5 participants. The study started on 2019-04-01. Estimated completion is 2021-05-31.
What interventions are being tested in trial NCT03943693?
The interventions under investigation include: Double shock (DEVICE), Single shock (DEVICE).
Who is sponsoring clinical trial NCT03943693?
This trial is sponsored by University of Oklahoma, which has 358 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.